1. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab. 2011; 22:9–15.
2. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol. 2012; 10:410–421.
3. Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013; 127:891–904.
4. Kopecky C, Haidinger M, Birner-Grünberger R, et al. Restoration of renal function does not correct impairment of uremic HDL properties. J Am Soc Nephrol. 2015; 26:565–575.
5. Darabi M, Guillas-Baudouin I, Le Goff W, Chapman MJ, Kontush A. Therapeutic applications of reconstituted HDL: when structure meets function. Pharmacol Ther. 2016; 157:28–42.
6. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009; 29:870–876.
7. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011; 121:2693–2708.
8. Rosenson RS, Brewer HB Jr, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013; 128:1256–1267.
9. Gordon SM, Chung JH, Playford MP, et al. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography. Atherosclerosis. 2018; 278:278–285.
10. Pamir N, Hutchins PM, Ronsein GE, et al. Plasminogen promotes cholesterol efflux by the ABCA1 pathway. JCI Insight. 2017; 2:e92176.
11. Luo M, Liu A, Wang S, et al. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep. 2017; 7:2312.
12. Rhainds D, Tardif JC. From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. Curr Opin Lipidol. 2019; 30:101–107.
13. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003; 10:541–544.
14. Singh B, Su YC, Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol. 2010; 78:545–560.
15. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007; 117:746–756.
16. Stonik JA, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun. 2004; 321:936–941.
17. Abe-Dohmae S, Kato KH, Kumon Y, et al. Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1- or ABCA7-dependent manner. J Lipid Res. 2006; 47:1542–1550.
18. van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem. 2005; 280:35890–35895.
19. Han CY, Tang C, Guevara ME, et al. Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest. 2016; 126:266–281.
20. Ceda GP, Dall'Aglio E, Magnacavallo A, et al. The insulin-like growth factor axis and plasma lipid levels in the elderly. J Clin Endocrinol Metab. 1998; 83:499–502.
21. Lam CS, Chen MH, Lacey SM, et al. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol. 2010; 30:1479–1484.
22. Min HK, Maruyama H, Jang BK, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J. 2016; 30:4071–4082.
23. Zhang Q, Steinle JJ. IGFBP-3 inhibits TNF-á production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis. Microvasc Res. 2014; 95:76–81.
24. Kawachi S, Takeda N, Sasaki A, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25:617–621.
25. Craword SE, Fitchev P, Veliceasa D, Volpert OV. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder? Expert Opin Drug Discov. 2013; 8:769–792.
26. Tahara N, Yamagishi S, Tahara A, et al. Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis. 2011; 219:311–315.
27. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 2005; 320:437–445.
28. Khan AA, Mundra PA, Straznicky NE, et al. Weight loss and exercise alter the high-density lipoprotein lipidome and improve high-density lipoprotein functionality in metabolic syndrome. Arterioscler Thromb Vasc Biol. 2018; 38:438–447.